Last reviewed · How we verify

DaunoXome — Competitive Intelligence Brief

DaunoXome (DaunoXome) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Liposomal anthracycline chemotherapy. Area: Oncology.

phase 3 Liposomal anthracycline chemotherapy DNA (topoisomerase II inhibitor) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

DaunoXome (DaunoXome) — Gruppo Italiano Malattie EMatologiche dell'Adulto. DaunoXome is a liposomal formulation of daunorubicin that intercalates into DNA and inhibits topoisomerase II, leading to DNA damage and cell death in rapidly dividing cells.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
DaunoXome TARGET DaunoXome Gruppo Italiano Malattie EMatologiche dell'Adulto phase 3 Liposomal anthracycline chemotherapy DNA (topoisomerase II inhibitor)
DSP DSP Taiwan Liposome Company marketed Liposomal anthracycline chemotherapy Topoisomerase II

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Liposomal anthracycline chemotherapy class)

  1. Gruppo Italiano Malattie EMatologiche dell'Adulto · 1 drug in this class
  2. Taiwan Liposome Company · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). DaunoXome — Competitive Intelligence Brief. https://druglandscape.com/ci/daunoxome. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: